International evaluation of MIC distributions and epidemiological cutoff value (ECV) definitions for Fusarium species identified by molecular methods for the CLSI broth microdilution method

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 2, 2016, Pages 1079-1084

  Espinel Ingroff, A ^a   Colombo, A L ^b   Cordoba, S ^c   Dufresne, P J ^d   Fuller, J ^e   Ghannoum, M ^f   Gonzalez, G M ^g   Guarro, J ^h   Kidd, S E ⁱ   Meis, J F ^j   Melhem, T M S C ^k   Pelaez, T ^l   Pfaller, M A ^m   Szeszs, M W ^k   Takahaschi, J P ⁿ   Tortorano, A M ^o   Wiederhold, N P ^p   Turnidge, J ^q  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c INSTITUTO NACIONAL DE ENFERMEDADES INFECCIOSAS   (Argentina)

^d INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^e ALBERTA HEALTH SERVICES   (Canada)

^f UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^g UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

^h INSTITUT D INVESTIGACIÓ SANITÀRIA PERE VIRGILI IISPV   (Spain)

ⁱ SA Pathology   (Australia)

^j RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^k INSTITUTO ADOLFO LUTZ   (Brazil)

^l HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^m JMI LABORATORIES   (United States)

ⁿ Fleury   (Brazil)

^o UNIVERSITY OF MILAN   (Italy)

^p UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^q UNIVERSITY OF ADELAIDE   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE; ANTIFUNGAL AGENT;

ANALYTICAL PARAMETERS; ANTIFUNGAL SUSCEPTIBILITY; ARGENTINA; ARTICLE; AUSTRALIA; BRAZIL; BROTH DILUTION; CANADA; EPIDEMIOLOGICAL CUTOFF VALUE; FUNGUS ISOLATION; FUSARIOSIS; FUSARIUM; FUSARIUM DIMERUM; FUSARIUM EQUISETI; FUSARIUM FUJIKUROI; FUSARIUM INCARNATUM; FUSARIUM OXYSPORUM; FUSARIUM PROLIFERATUM; FUSARIUM SOLANI; FUSARIUM VERTICILLIOIDES; GENE MUTATION; MEXICO; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR MECHANICS; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SPECIES DIFFERENCE; DRUG EFFECTS; EUROPE; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE; PROCEDURES; WESTERN HEMISPHERE;

AMERICAS; ANTIFUNGAL AGENTS; DRUG RESISTANCE, MULTIPLE, FUNGAL; EUROPE; FUSARIUM; HUMANS; MICROBIAL SENSITIVITY TESTS; POLYMERASE CHAIN REACTION;

EID: 84957922232     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02456-15     Document Type: Article

References (40)

1. Guarro J. 2013. Fusariosis, a complex infection caused by a high diversity of fungal species refractory to treatment. Eur J Clin Microbiol Infect Dis 32:1491-1500. http://dx.doi.org/10.1007/s10096-013-1924-7.
2. O'Donnell K, Sutton DA, Fothergill A, McCarthy D, Rinaldi MG, Brandt ME, Zhang N, Geiser DM. 2008. Molecular phylogenetic diversity, multilocus haplotype nomenclature, and in vitro antifungal resistance within the Fusarium solani species complex. J Clin Microbiol 46:2477-2490. http://dx.doi.org/10.1128/JCM.02371-07.
3. O'Donnell K, Sutton DA, Rinaldi MG, Sarver BA, Balajee SA, Schroers HJ, Summerbell RC, Robert VA, Crous PW, Zhang N, Aoki T, Jung K, Park J, Lee YH, Kang S, Park B, Geiser DM. 2010. Internet-accessible DNA sequence database for identifying fusaria from human and animal infections. J Clin Microbiol 48:3708-3718. http://dx.doi.org/10.1128/JCM.00989-10.
4. Tortorano AM, Prigitano A, Esposto MC, Arsic Arsenijevic V, Kolarovic J, Ivanovic D, Paripovic L, Klingspor L, Nordøy I, Hamal P, Arikan Akdagli S, Ossi C, Grancini A, Cavanna C, Lo Cascio G, Scarparo C, Candoni A, Caira M, Drogari Apiranthitou M, ECMM Working Group. 2014. European Confederation of Medical Mycology (ECMM) epidemiological survey on invasive infections due to Fusarium species in Europe. Eur J Clin Microbiol Infect Dis 33:1623-1630. http://dx.doi.org/10.1007/s10096-014-2111-1.
5. McNeill J, Barrie FR, Buck WR, Demoulin V, Greuter W, Hawksworth DL, Herendeen PS, Knapp S, Marhold K, Prado J, Proud'homme van Reine WF, Smith GF, Wiersema JH, Turland NJ. 2012. International code of nomenclature for algae, fungi and plants (Melbourne Code) adopted by the Eighteenth International Botanical Congress, Melbourne, Australia, July 2011. Koeltz Scientific Books, Koenigstein, Germany.
6. Lombard L, van der Merwe NA, Groenewald JZ, Crous PW. 2014. Generic concepts in Nectriaceae. Stud Mycol 80:189-245.
7. Muhammed M, Anagnostou T, Desalermos A, Kourkoumpetis TK, Carneiro HA, Glavis-Bloom J, Coleman JJ, Mylonakis E. 2013. Fusarium infection: report of 26 cases and review of 97 cases from the literature. Medicine 92:305-316. http://dx.doi.org/10.1097/MD.0000000000000008.
8. Nir-Paz R, Strahilevitz J, Shapiro M, Keller N, Goldschmied-Reouven A, Yarden O, Block C, Polacheck I. 2004. Clinical and epidemiological aspects of infections caused by Fusarium species: a collaborative study from Israel. J Clin Microbiol 42:3456-3461. http://dx.doi.org/10.1128/JCM.42.8.3456-3461.2004.
9. Scheel CM, Hurst SF, Barreiros G, Akiti T, Nucci M, Balajee SA. 2013. Molecular analyses of Fusarium isolates recovered from a cluster of invasive mold infections in a Brazilian hospital. BMC Infect Dis 13:49. http://dx.doi.org/10.1186/1471-2334-13-49.
10. van Diepeningen AD, Al-Hatmi AMS, Brankovics B, de Hoog GS. 2014. Taxonomy and clinical spectra of Fusarium species: where do we stand in 2014? Curr Clin Microbiol Rep 1:10-18. http://dx.doi.org/10.1007/s40588-014-0003-x.
11. Garnica M, daCunha OM, Portugal R, Maiolino A, Colombo AL, Nucci MM. 2015. Risk factors for invasive fusariosis in patients with acute myeloid leukemia and in hematopoietic cell transplant recipients. Clin Infect Dis 60:875-880. http://dx.doi.org/10.1093/cid/ciu947.
12. Homa M, Shobana CS, Singh YR, Manikandan P, Selvam KP, Kredics L, Narendran V, Vagvolgyi C, Galgoczy L. 2013. Fusarium keratitis in South India: causative agents, their antifungal susceptibilities and a rapid identification method for the Fusarium solani species complex. Mycoses 56:501-511. http://dx.doi.org/10.1111/myc.12062.
13. Chang DC, Grant GB, O'Donnell K, Wannemuehler KA, Noble-Wang J, Rao CY, Jacobson LM, Crowell CS, Sneed RS, Lewis FM, Schaffzin JK, Kainer MA, Genese CA, Alfonso EC, Jones DB, Srinivasan A, Fridkin SK, Park BJ. 2006. Multistate outbreak of Fusarium keratitis associated with use of a contact lens solution. JAMA 23:953-963. http://dx.doi.org/10.1001/jama.296.8.953.
14. Vazquez JA, Miceli MH, Alangaden G. 2013. Invasive fungal infections in transplant recipients. Ther Adv Infect Dis 3:85-105. http://dx.doi.org/10.1177/2049936113491936.
15. Cocchi S, Codeluppi M, Venturelli C, Bedini A, Grottola A, Gennari W, Cavrini F, Di Benedetto F, De Ruvo N, Rumpianesi F, Gerunda GE, Guaraldi G. 2011. Fusarium verticillioides fungemia in a liver transplantation patient: successful treatment with voriconazole. Diagn Microbiol Infect Dis 71:438-441. http://dx.doi.org/10.1016/j.diagmicrobio.2011.08.024.
16. Lortholary O, Obenga G, Biswas P, Caillot D, Chachaty E, Bienvenu AL, Cornet M, Greene J, Herbrecht R, Lacroix C, Genouillet F, Raad I, Sitbon K, Troke P, French Mycoses Study Group. 2010. International retrospective analysis of 73 cases of invasive fusariosis. Antimicrob Agents Chemother 54:4446-4450. http://dx.doi.org/10.1128/AAC.00286-10.
17. Perfect JR, Marr KA, Walsh TJ, Greenberg RN, DuPont B, de la Torre-Cisneros J, Just-Nübling G, Schlamm HT, Lutsar I, Espinel-Ingroff A, Johnson E. 2003. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 36:1122-1131. http://dx.doi.org/10.1086/374557.
18. Raad I, Hachem R, Herbrech R, Graybill JR, Hare R, Corcoran G, Kontoyannis DP. 2006. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 42:1398-1403. http://dx.doi.org/10.1086/503425.
19. Tortorano AM, Richardson M, Roilides E, van Diepeningen A, Caira M, Munoz P, Johnson E, Meletiadis J, Pana ZD, Lackner M, Verweij P, Freiberger T, Cornely OA, Arikan-Akdagli S, Dannaoui E, Groll AH, Lagrou K, Chakrabarti A, Lanternier F, Pagano L, Skiada A, Akova M, Arendrup MC, Boekhout T, Chowdhary A, Cuenca-Estrella M, Guinea J, Guarro J, de Hoog S, Hope W, Kathuria S, Lortholary O, Meis JF, Ullmann AJ, Petrikkos G, Lass-Flörl C, European Society of Clinical Microbiology and Infectious Diseases Fungal Infection Study Group, European Confederation of Medical Mycology. 2014. ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. Clin Microbiol Infect 20:27-46. http://dx.doi.org/10.1111/1469-0691.12465.
20. Nucci M, Anaissie E. 2007. Fusarium infections in immunocompromised patients. Clin Microbiol Rev 20:695-704. http://dx.doi.org/10.1128/CMR.00014-07.
21. Nucci M, Anaissie E, Queiroz-Telles F, Martins CA, Trabasso P, Solza C, Mangini C, Simoes BP, Colombo AL, Vaz J, Levy CE, Costa S, Moreira VA, Oliveira JS, Paraguay N, Duboc G, Voltarelli JC, Maiolino A, Pasquini R, Souza CA. 2003. Outcome predictor of 84 patients with hematologic malignancies and Fusarium infection. Cancer 98:315-319. http://dx.doi.org/10.1002/cncr.11510.
22. Stempel JM, Hammond SP, Sutton DA, Weiser LM, Marty FM. 2015. Invasive fusariosis in the voriconazole era: single-center 13-year experience. Open Forum Infect Dis 2:ofv099. http://dx.doi.org/10.1093/ofid/ofv099.
23. Maertens J, Cornely OA, Ullmann AJ, Heinz WJ, Krishna G, Patino H, Caceres M, Kartsonis N, Waskin H, Robertson MN. 2014. Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease. Antimicrob Agents Chemother 58:3610-3617. http://dx.doi.org/10.1128/AAC.02686-13.
24. Abuhelwa AY, Foster DJR, Mudge S, Hayes D, Upton RN. 2015. Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and Sporanox capsule formulations in healthy subjects in fed and fasted states. Antimicrob Agents Chemother 59:5681-5696. http://dx.doi.org/10.1128/AAC.00973-15.
25. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard, 2nd ed. CLSI document M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
26. Espinel-Ingroff A, Chakrabarti A, Chowdhary A, Cordoba S, Dannaoui E, Dufresne P, Fothergill A, Ghannoum M, Gonzalez GM, Guarro J, Kidd S, Lass-Flörl C, Meis JF, Pelaez T, Tortorano AM, Turnidge J. 2015. Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of Mucorales. Antimicrob Agents Chemother 59:1745-1750. http://dx.doi.org/10.1128/AAC.04435-14.
27. Espinel-Ingroff A, Alvarez-Fernandez M, Cantón E, Carver PL, Chen SC-A, Eschenauer G, Getsinger DL, Gonzalez GM, Govender NP, Grancini A, Hanson KE, Kidd SE, Klinker K, Kubin CJ, Kus JV, Lockhart SR, Meletiadis J, Morris AJ, Pelaez T, Quindós G, Rodriguez-Iglesias M, Sánchez-Reus F, Shoham S, Wengenack NL, Borrell Solé N, Echeverria J, Esperalba J, Gómez-García de la Pedrosa E, García García I, Linares MJ, Marco F, Merino P, Pemán J, Pérez del Molino L, Roselló Mayans E, Rubio Calvo C, Ruiz Pérez de Pipaon M, Yagüe G, Garcia-Effron G, Guinea J, Perlin DS, Sanguinetti M, Shields R, Turnidge J. 2015. Multicenter study of epidemiological cutoff values and detection of resistance in Candida spp. to anidulafungin, caspofungin, and micafungin using the Sensititre YeastOne colorimetric method. Antimicrob Agents Chemother 59:6725-6732. http://dx.doi.org/10.1128/AAC.01250-15.
28. Alastruey-Izquierdo A, Cuenca-Estrella M, Monzon A, Mellado E, Rodriguez-Tudela JL. 2008. Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods. J Antimicrob Chemother 61:805-809. http://dx.doi.org/10.1093/jac/dkn022.
29. Arikan S, Lozano-Chiu M, Paetznick V, Nangia S, Rex JH. 1999. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species. J Clin Microbiol 37:3946-3951.
30. Castanheira M, Duncanson FP, Diekema DJ, Guarro J, Jones RN, Pfaller MA. 2012. Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods. Antimicrob Agents Chemother 56:352-357. http://dx.doi.org/10.1128/AAC.05414-11.
31. Espinel-Ingroff A, Johnson E, Hockey H, Troke P. 2008. Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole phase III clinical studies. J Antimicrob Chemother 61:616-620. http://dx.doi.org/10.1093/jac/dkm518.
32. Leslie JF, Summerell BA. 2006. The Fusarium laboratory manual. Blackwell Publishing, Ames, IA.
33. Al-Hatmi AM, van Diepeningen AD, Curfs-Breuker I, de Hoog GS, Meis JF. 2015. Specific antifungal susceptibility profiles of opportunists in the Fusarium fujikuroi complex. J Antimicrob Chemother 70:1068-1071. http://dx.doi.org/10.1093/jac/dku505.
34. O'Donnell K, Sutton DA, Rinaldi MG, Gueidan C, Crous PW, Geiser DM. 2009. Novel multilocus sequence typing scheme reveals high genetic diversity of human-pathogenic members of the Fusarium incarnatum-F. equiseti and F. chlamydosporum species complexes within the United States. J Clin Microbiol 47:3851-3861. http://dx.doi.org/10.1128/JCM.01616-09.
35. Turnidge J, Kahmeter G, Kronvall G. 2006. Statistical characterization of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin Microbiol Infect 12:418-425. http://dx.doi.org/10.1111/j.1469-0691.2006.01377.x.
36. Turnidge J, Paterson DL. 2007. Setting and revising antibacterial susceptibility breakpoints. Clin Microbiol Rev 20:391-408. http://dx.doi.org/10.1128/CMR.00047-06.
37. Dalhoff A, Ambrose PG, Mouton JW. 2009. A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints. Infection 37:296-305. http://dx.doi.org/10.1007/s15010-009-7108-9.
38. Clinical and Laboratory Standards Institute. 2012. Reference method for broth dilution antifungal susceptibility testing of yeasts; 4th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
39. Espinel-Ingroff A, Cuenca-Estrella M, Fothergill A, Fuller J, Ghannoum M, Johnson E, Pelaez T, Pfaller MA, Turnidge J. 2011. Wild-type MIC distributions and epidemiological cutoff values for amphotericin B and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). Antimicrob Agents Chemother 55:5150-5154. http://dx.doi.org/10.1128/AAC.00686-11.
40. Andes D, Pascual A, Marchetti O. 2009. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 53:24-34. http://dx.doi.org/10.1128/AAC.00705-08.